The natural history of treated Parkinson's disease in an incident, community based cohort
BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be i...
Gespeichert in:
Veröffentlicht in: | Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1118 |
---|---|
container_issue | 10 |
container_start_page | 1112 |
container_title | Journal of neurology, neurosurgery and psychiatry |
container_volume | 82 |
creator | Evans, Jonathan R Mason, Sarah L Williams-Gray, Caroline H Foltynie, Thomas Brayne, Carol Robbins, Trevor W Barker, Roger A |
description | BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients. |
doi_str_mv | 10.1136/jnnp.2011.240366 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907182219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907182219</sourcerecordid><originalsourceid>FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</originalsourceid><addsrcrecordid>eNqNkdtrFDEUxoNY7Lb67pMERPpgZ81lJjPzqEvV0lIr1NtTyJWddSZZkwy4_70ZZu2CUDAPJ4TzO1_O-Q4AzzFaYkzZm41z2yVBGC9JiShjj8ACl6wpKEXfH4MFQoQUFFXoGJzEuEHTadon4JjgqqUVpgvw425toBNpDKKH6y4mH3bQW5iCEcloeCvCz85F784i1F00IhrYOShcjqrTxqVzqPwwjK5LOyhzWuf32of0FBxZ0UfzbH-fgi_vL-5WH4vrTx8uV2-vC8lQnQrSMqklrapSM6uQanHDZCMwKTUubaNsrZC1VtUlQ1ILJFRFtS4boohEtpb0FJzNutvgf40mJj50UZm-F874MfIW1bghBLeZfPkPufFjcLk5jusm_8gwoZlCM6WCjzEYy7ehG0TYcYz45DqfXOeT63x2PZe82AuPcjD6vuCvzRl4tQdEVKK3QWTz4oErK5qlJqFi5vIizO_7fN4BZzWtK37zdcU_t-SGXr37xm8z_3rm5bD5nzbPD_Rh9IfwP5IxtU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781246123</pqid></control><display><type>article</type><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</creator><creatorcontrib>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</creatorcontrib><description>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp.2011.240366</identifier><identifier>PMID: 21593513</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Activities of daily living ; Age Factors ; Aged ; Antiparkinson Agents - therapeutic use ; Biological and medical sciences ; Clinical trials ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dementia ; Dementia - diagnosis ; Dementia - drug therapy ; Disease Progression ; Female ; Genotype ; Haplotypes - genetics ; Humans ; Kaplan-Meier Estimate ; Levodopa - therapeutic use ; Male ; Medical sciences ; Mortality ; Neurologic Examination - drug effects ; Neurology ; Neuropsychological Tests ; Parkinson Disease - diagnosis ; Parkinson Disease - drug therapy ; Parkinson's disease ; Pathology ; Quality of Life ; Research paper ; Studies ; tau Proteins - genetics</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>2011 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jnnp.bmj.com/content/82/10/1112.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jnnp.bmj.com/content/82/10/1112.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,55321,77342,77373,77401,77427</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24532406$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21593513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Mason, Sarah L</creatorcontrib><creatorcontrib>Williams-Gray, Caroline H</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><creatorcontrib>Brayne, Carol</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</description><subject>Activities of daily living</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dementia</subject><subject>Dementia - diagnosis</subject><subject>Dementia - drug therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Genotype</subject><subject>Haplotypes - genetics</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Neurologic Examination - drug effects</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Pathology</subject><subject>Quality of Life</subject><subject>Research paper</subject><subject>Studies</subject><subject>tau Proteins - genetics</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkdtrFDEUxoNY7Lb67pMERPpgZ81lJjPzqEvV0lIr1NtTyJWddSZZkwy4_70ZZu2CUDAPJ4TzO1_O-Q4AzzFaYkzZm41z2yVBGC9JiShjj8ACl6wpKEXfH4MFQoQUFFXoGJzEuEHTadon4JjgqqUVpgvw425toBNpDKKH6y4mH3bQW5iCEcloeCvCz85F784i1F00IhrYOShcjqrTxqVzqPwwjK5LOyhzWuf32of0FBxZ0UfzbH-fgi_vL-5WH4vrTx8uV2-vC8lQnQrSMqklrapSM6uQanHDZCMwKTUubaNsrZC1VtUlQ1ILJFRFtS4boohEtpb0FJzNutvgf40mJj50UZm-F874MfIW1bghBLeZfPkPufFjcLk5jusm_8gwoZlCM6WCjzEYy7ehG0TYcYz45DqfXOeT63x2PZe82AuPcjD6vuCvzRl4tQdEVKK3QWTz4oErK5qlJqFi5vIizO_7fN4BZzWtK37zdcU_t-SGXr37xm8z_3rm5bD5nzbPD_Rh9IfwP5IxtU0</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Evans, Jonathan R</creator><creator>Mason, Sarah L</creator><creator>Williams-Gray, Caroline H</creator><creator>Foltynie, Thomas</creator><creator>Brayne, Carol</creator><creator>Robbins, Trevor W</creator><creator>Barker, Roger A</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope></search><sort><creationdate>20111001</creationdate><title>The natural history of treated Parkinson's disease in an incident, community based cohort</title><author>Evans, Jonathan R ; Mason, Sarah L ; Williams-Gray, Caroline H ; Foltynie, Thomas ; Brayne, Carol ; Robbins, Trevor W ; Barker, Roger A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b607t-296bdb3554d6fc0c9186b8a124d14f8cf7c0fffc7460bda0ac53dd482c2b0f7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Activities of daily living</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dementia</topic><topic>Dementia - diagnosis</topic><topic>Dementia - drug therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Genotype</topic><topic>Haplotypes - genetics</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Neurologic Examination - drug effects</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Pathology</topic><topic>Quality of Life</topic><topic>Research paper</topic><topic>Studies</topic><topic>tau Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, Jonathan R</creatorcontrib><creatorcontrib>Mason, Sarah L</creatorcontrib><creatorcontrib>Williams-Gray, Caroline H</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><creatorcontrib>Brayne, Carol</creatorcontrib><creatorcontrib>Robbins, Trevor W</creatorcontrib><creatorcontrib>Barker, Roger A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Journals (ProQuest Database)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, Jonathan R</au><au>Mason, Sarah L</au><au>Williams-Gray, Caroline H</au><au>Foltynie, Thomas</au><au>Brayne, Carol</au><au>Robbins, Trevor W</au><au>Barker, Roger A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The natural history of treated Parkinson's disease in an incident, community based cohort</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><stitle>J Neurol Neurosurg Psychiatry</stitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>82</volume><issue>10</issue><spage>1112</spage><epage>1118</epage><pages>1112-1118</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>BackgroundOur understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.MethodsA representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn–Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr`aphic, clinical and genetic variables was evaluated using survival analysis.ResultsAxial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn–Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.ConclusionsDementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><pmid>21593513</pmid><doi>10.1136/jnnp.2011.240366</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3050 |
ispartof | Journal of neurology, neurosurgery and psychiatry, 2011-10, Vol.82 (10), p.1112-1118 |
issn | 0022-3050 1468-330X |
language | eng |
recordid | cdi_proquest_miscellaneous_907182219 |
source | MEDLINE; BMJ Journals - NESLi2 |
subjects | Activities of daily living Age Factors Aged Antiparkinson Agents - therapeutic use Biological and medical sciences Clinical trials Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dementia Dementia - diagnosis Dementia - drug therapy Disease Progression Female Genotype Haplotypes - genetics Humans Kaplan-Meier Estimate Levodopa - therapeutic use Male Medical sciences Mortality Neurologic Examination - drug effects Neurology Neuropsychological Tests Parkinson Disease - diagnosis Parkinson Disease - drug therapy Parkinson's disease Pathology Quality of Life Research paper Studies tau Proteins - genetics |
title | The natural history of treated Parkinson's disease in an incident, community based cohort |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20natural%20history%20of%20treated%20Parkinson's%20disease%20in%20an%20incident,%20community%20based%20cohort&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Evans,%20Jonathan%20R&rft.date=2011-10-01&rft.volume=82&rft.issue=10&rft.spage=1112&rft.epage=1118&rft.pages=1112-1118&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp.2011.240366&rft_dat=%3Cproquest_cross%3E907182219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781246123&rft_id=info:pmid/21593513&rfr_iscdi=true |